Forte Biosciences, Inc.
FBRX
$6.32
-$0.34-5.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.41M | 16.10M | 17.19M | 12.01M | 10.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.60M | 35.63M | 37.22M | 33.44M | 32.49M |
| Operating Income | -36.60M | -35.63M | -37.22M | -33.44M | -32.49M |
| Income Before Tax | -35.48M | -34.20M | -35.76M | -32.14M | -31.48M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -35.48 | -34.20 | -35.76 | -32.14 | -31.48 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.48M | -34.20M | -35.76M | -32.14M | -31.48M |
| EBIT | -36.60M | -35.63M | -37.22M | -33.44M | -32.49M |
| EBITDA | -36.56M | -35.60M | -37.19M | -24.39M | -16.59M |
| EPS Basic | -16.52 | -18.53 | -20.56 | -24.34 | -28.36 |
| Normalized Basic EPS | -10.32 | -11.58 | -12.85 | -15.22 | -17.72 |
| EPS Diluted | -16.52 | -18.53 | -20.56 | -24.34 | -28.36 |
| Normalized Diluted EPS | -10.32 | -11.58 | -12.85 | -15.22 | -17.72 |
| Average Basic Shares Outstanding | 11.66M | 7.38M | 7.05M | 6.05M | 5.04M |
| Average Diluted Shares Outstanding | 11.66M | 7.38M | 7.05M | 6.05M | 5.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |